The Center for Business Intelligence (CBI) will be holding its Pharmaceutical Congress on Paragraph IV Disputes on October 15-16 in Philadelphia, PA. The conference will cover important issues for both brand and generic companies during two days of presentations and panel discussions on litigation strategies, statutory guidelines, current cases, and their landmark decisions. Topics to be discussed at the conference include:
• FTC address on pharmaceutical antitrust;
• In-depth analysis of recent court cases and their implications on brand and generic companies;
• Effects of KSR on brand and generic litigation strategies;
• Panel discussion on acceptable settlement strategies for Paragraph IV disputes;
• Litigating Paragraph IV disputes with multiple ANDA filers;
• Interpreting forfeiture provisions for better business decisions;
• Pre-suit preparedness strategies for Paragraph IV disputes;
• Citizen petitions and their impact on generic entry;
• Declaratory judgments; and
• At risk launches.
Among the presentations and panel discussions that CBI faculty will be providing are:
• Strategies to optimize patent lifecycle from drafting to maturity;
• Preparing for Paragraph IV challenges -- generic pre-suit strategies;
• Best practices in e-discovery -- overcoming obstacles, controlling costs and maximizing benefits;
• The KSR decision and ANDA litigation;
• Lessons from the court -- examine the proceedings of a key victory on an important case;
• Implications of recent developments and trends in litigating Paragraph IV disputes;
• Citizen petitions and their impact on generic entry;
• Interpreting forfeiture provisions -- an analysis of recent cases to increase preparedness and improve product strategy;
• The FTC, antitrust law, and settling Paragraph IV litigation; and
• Acceptable settlement strategies for Paragraph IV disputes.
An additional pre-conference workshop entitled: "Litigation Strategies to Proactively Plan for Paragraph IV Disputes" will be offered on October 15, 2008. The pre-conference workshop will set up a mock Paragraph IV dispute, with a hypothetical patent, from the initial certification through disposition of the suit, addressing all options for both the innovator and generic companies along the way.
The agenda for the Pharmaceutical Congress on Paragraph IV Disputes can be found here. A brochure for this conference can be requested here.
The registration fee for the conference is $1,995. Attendees registering on or before August 15, 2008 will receive a $300 discount off the registration fee, and attendees registering a group of three individuals will receive a fourth registration for free. Those interested in registering for the conference can do so here, by calling 1-800-817-8601, or by e-mail at [email protected].
Patent Docs is a media sponsor of CBI's Pharmaceutical Congress on Paragraph IV Disputes.
Comments